NICE Appraisals & Guidelines

CancerBACUP submits evidence to NICE technology appraisals and makes submissions to cancer service guidelines.

Recent submissions:

1. CancerBACUP submitted detailed evidence to NICE on the patient’s perspective on rituximab (MabThera) for aggressive non-Hodgkin’s lymphoma and recommended that rituximab should be available as a first-line treatment to patients on the NHS. Final guidance on rituximab for aggressive non-Hodgkin’s lymphoma was issued in September 2003 and agreed with CancerBACUP’s recommendation.
    
2. CancerBACUP submitted detailed evidence to NICE on the patient’s perspective on imatinib (Glivec) for CML and recommended that imatinib should be available as a first-line treatment to patients on the NHS.  Final guidance on imatinib for CML was issued in October 2003 and agreed with CancerBACUP’s recommendation.
    
3. CancerBACUP submitted a detailed response to the NICE draft guidance on supportive and palliative care. We made a further joint response on general points with other charities including Macmillan, Prostate Cancer Charity and Breakthrough Breast Cancer. A second round of consultation on this guidance is currently taking place, with full guidance due in February 2004.
    
4. CancerBACUP also submitted a detailed response to the first and second rounds of consultation on draft service guidance for colorectal cancer. Final guidance on this guidance is due on 2004
    .
5. CancerBACUP has also submitted comments to the draft scope on NICE service guidance for skin tumours.
    
6. CancerBACUP’s Genetic Information Project Manager submitted a detailed response to NICE draft guidance on Familial Breast Cancer.  Breakthrough Breast Cancer and Breast Cancer Care have endorsed many of our recommendations in their own responses.